Catalent has completed the acquisition of Cook Pharmica LLC, an IN-based provider of drug substance and drug product manufacturing and related services, paying approximately $1.7 billion. The acquisition expands Catalent’s biologics development and analytical services, manufacturing and finished product supply.     Catalent has reorganized its operations to create two new dedicated business units. With substantially increased biopharmaceutical and fill-finish capabilities and the rapidly growi...